Italy has pledged to participate in ELIXIR (www.elixir-europe.org), a major undertaking to safeguard the results of life science research in Europe. With one of Europe's larger economies now demonstrating its commitment to ELIXIR, this burgeoning research infrastructure is well placed to continue its excellent progress.
ELIXIR is a pan-European effort to operate a sustainable infrastructure for managing biological data to support research and its translation into medicine, the environment, the bio-industries and society. Its goal is to secure open, public access to information about the building blocks of life in the interests of expediting discovery in the life sciences. Freely available and on-going access to biological data is key to ensuring that such discoveries can be translated to solutions to some of the most pressing challenges facing society today.
As ELIXIR enters its construction phase, its pivotal role in facilitating research and development throughout Europe has become increasingly clear. Italy joins the European Molecular Biology Laboratory (EMBL, www.embl.org) and 11 other nations in signing a Memorandum of Understanding (MoU) for ELIXIR: Denmark, Estonia, Finland, Israel, the Netherlands, Norway, Slovenia, Spain, Sweden, Switzerland and the United Kingdom have already pledged their support. All European countries are invited to engage with ELIXIR.
Signing the MoU is a first formal yet non-binding step towards the implementation of ELIXIR. Countries that join EMBL in signing the MoU have representation on the Interim Board, which is chaired by Sren Brunak of the Technical University of Denmark and is the main body negotiating the final legal and governance structure of ELIXIR.
'The Italian participation in ELIXIR is a major step towards the construction of this key European research infrastructure," s
|Contact: Lindsey Crosswell|
European Molecular Biology Laboratory - European Bioinformatics Institute